Stay updated on DUET Clinical Trial: Sparsentan in FSGS.
Sign up to get notified when there's something new on the DUET Clinical Trial: Sparsentan in FSGS. page.

Latest updates to the DUET Clinical Trial: Sparsentan in FSGS. page
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about a study on RE-021 for treating focal segmental glomerulosclerosis, while adding a new revision number and the term 'Focal Segmental Glomerulosclerosis'.SummaryDifference40%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe page has updated the name of the medical school from NYU Grossman School of Medicine to NYU School of Medicine, and it now includes a notice about heavy traffic affecting NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to DUET Clinical Trial: Sparsentan in FSGS.
Enter your email address, and we'll notify you when there's something new on the DUET Clinical Trial: Sparsentan in FSGS. page.